Company intelligence / Profile preview
Cynata Therapeutics
Carlton, Victoria, Australiacynata.com ↗
- Ownership
- Public · CYP
- Employees
- ~20
- Development stage
- Phase 2
01
Overview
Cynata’s lead product candidate CYP‑001 has completed a successful Phase I trial in steroid-resistant acute GvHD with positive safety and efficacy results. A global Phase II trial for high-risk aGvHD is ongoing. The company also has an osteoarthritis program in Phase III trials and additional clinical/preclinical programs targeting diabetic foot ulcers and other conditions. The Cymerus platform enables consistent large-scale production of MSCs from a single donor iPSC line—addressing key manufacturing challenges in the field[1][2][4][6].
- Therapeutic areas
- PulmonologyCardiovascularRheumatologyNephrologyImmunologyEndocrinologyInfectious Diseases
- Modalities
- Induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)Cell and gene therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Fujifilm – strategic partnership for manufacturing scale-up and development/commercialization of Cymerus products in certain territories/disease areas[2].
Beyond the preview
Go deeper on Cynata Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cynata Therapeutics.